Introduction
============

Fibromyalgia is a rheumatic condition characterized by chronic pain, fatigue, and other physical and/or psychological symptoms.[@b1-jpr-9-967] It is commonly associated with a variety of comorbidities, including, but not limited to, migraines and sleep difficulties,[@b2-jpr-9-967],[@b3-jpr-9-967] and also with mental health conditions, such as anxiety and depression.[@b4-jpr-9-967] Recently, in Japan, the prevalence of fibromyalgia was estimated to be 2.1% among adults (aged ≥20 years), with the majority (60.5%) of them being female.[@b5-jpr-9-967]

The American College of Rheumatology (ACR) guidelines indicate that diagnosis of fibromyalgia is warranted based on patients' scores on the Widespread Pain Index (≥7) and Symptom Severity Scale (≥5; or Widespread Pain Index score of 3--6 coupled with Symptom Severity Scale score ≥9), symptoms that have consistently recurred for at least 3 months, and no condition otherwise present that would account for the pain experienced by the patient.[@b1-jpr-9-967] The diagnostic criteria in the ACR guidelines have been validated for the diagnosis of fibromyalgia patients in Japan.[@b6-jpr-9-967]

Although the epidemiology of fibromyalgia has been well examined in Japan, most of the research on health-related quality of life (HRQoL) or economic burden has been conducted in Western countries. Among Portuguese women, fibromyalgia was negatively associated with all dimensions of HRQoL, and the largest decreases were observed for physical functioning, physical role functioning, and general health.[@b7-jpr-9-967] US adults (aged ≥18 years) diagnosed with fibromyalgia reported poorer sleep quality and health status, as well as more severe pain, than those with or without chronic pain.[@b8-jpr-9-967] Another study on US adults (aged 18--65 years) demonstrated that severity has an impact on degree of burden; those with severe fibromyalgia self-reported greater pain intensity and fatigue, with poorer sleep quality, HRQoL, and mental health (anxiety and depression), than those with either moderate or mild fibromyalgia.[@b9-jpr-9-967] Moreover, several studies reveal that the health burden of fibromyalgia is greater than that of other similar chronic conditions. A Turkish study found that patients with fibromyalgia reported lower HRQoL than those with rheumatoid arthritis.[@b10-jpr-9-967] A Japanese study found that individuals with fibromyalgia experienced greater symptom severity and number of symptoms than patients with chronic pain.[@b5-jpr-9-967]

Compared to controls, US adults with fibromyalgia had higher health care resource use over the course of 1 year, including hospitalizations, visits to medical specialists, and total number of medical visits.[@b11-jpr-9-967] Furthermore, US patients with fibromyalgia (vs those with or without chronic pain) had greater health care resource use, including medications, supplements, health care provider visits, emergency room (ER) visits, and physical treatments.[@b10-jpr-9-967] Collectively, these findings suggest that direct costs for health care resource use are likely to be substantially higher among adults with fibromyalgia. Moreover, other studies have shown that even greater direct costs can be incurred when the severity of fibromyalgia symptoms increases.[@b12-jpr-9-967]

In addition, fibromyalgia has a negative impact on work productivity; more than half (55.8%) of working-age (\<65 years old) US adults with fibromyalgia reported being unable to work because of their health (vs only 5.8% of those without fibromyalgia).[@b11-jpr-9-967] These effects on work productivity can differ by severity, which has implications for indirect costs. For example, more than half (60%) of US adults with severe fibromyalgia reported work disruptions, due to their condition, compared to 45% and 15% of those with moderate or mild fibromyalgia, respectively.[@b10-jpr-9-967] Similarly, those with severe fibromyalgia missed an average of 3 days of work per month (39 days annually), whereas adults with moderate (1 day per month, 13 days annually) or mild (0.4 days per month, 5 days annually) fibromyalgia missed substantially less work. US adults with severe fibromyalgia had significantly greater 3-month direct (\$2,329) and indirect (\$8,285) costs than those with either moderate (\$1,415 direct and \$5,139 indirect) or mild (\$1,213 direct and \$1,341 indirect) fibromyalgia.[@b12-jpr-9-967] However, regardless of severity of fibromyalgia, indirect costs accounted for the majority of these patients' total costs.

Only a few research studies investigating the health and economic burden of fibromyalgia are available in Japan. The available research studies on the burden of fibromyalgia are incomplete, as more studies, to date, have been conducted in the US or EU. Therefore, it is unclear whether findings can be generalized to Japanese adults with fibromyalgia. The few studies using data from Japan include only a limited number of outcomes (eg, symptom severity, but not HRQoL or costs), or they are not fibromyalgia-specific (eg, all chronic pain conditions examined in the aggregate). Hence, to overcome the limitations in the existing literature, the present study sought to explore differences between Japanese adults with fibromyalgia and those without fibromyalgia on health status, sleep difficulties, work productivity and activity impairment, health care resource use, and associated costs. Results from this study can help to clarify better the health and economic burdens of fibromyalgia among Japanese adults.

Materials and methods
=====================

Data source
-----------

Data from the 2011--2014 Japan National Health and Wellness Survey (NHWS) were analyzed in this study. The data for all 4 years were combined to maximize the sample size. As respondents could participate in multiple survey years, most recent data of respondents were retained for analyses. In particular, all unique respondents from the 2011--2014 Japan NHWS (n=115,271) were initially included in the analyses ([Figure 1](#f1-jpr-9-967){ref-type="fig"}).

The recruitment of panel members in the Japan NHWS strived to approximate the distribution of adults in the Japanese population. More details on the Japan NHWS participant recruitment procedures and sampling framework have been reported in another study.[@b13-jpr-9-967] The survey was approved by Essex Institutional Review Board, Inc. (Lebanon, NJ, USA), and informed consent was obtained from all respondents prior to participation in the present study.

Measures
--------

### Fibromyalgia

Respondents who self-reported a diagnosis of fibromyalgia from a health care provider were considered to have fibromyalgia, and all other respondents were considered not to have fibromyalgia (ie, control respondents). A propensity score matching approach was used to match fibromyalgia respondents with control respondents, based on demographics and health characteristics.

### Demographics

Demographic variables included year of survey participation (2011, 2012, 2013, or 2014), sex (male or female), age, education (university degree vs all others), household income (¥) (\<¥3 MM, ¥3 MM to \<¥5 MM, ¥5 MM to \<¥8 MM, ≥¥8 MM, or decline to answer), and health insurance (national health insurance, social insurance, late-stage elderly insurance, others, or no insurance).

### Health history

Health history included smoking status (current smoker, former smoker, or never smoker), exercise behavior (whether exercised for 20 minutes in ≥1 day/month or did not exercise in the past month), alcohol consumption (consumes or abstains from alcohol), body mass index category (based on the recommendations of the World Health Organization[@b14-jpr-9-967] for Asian populations: underweight \[\<18.5kg/m^2^\], acceptable risk \[18.5 to \<23kg/m^2^\], increased risk \[23 to \<27.5kg/m^2^\], high risk \[≥27.5kg/m^2^\], or decline to provide weight), and the Charlson comorbidity index, a measure assessing comorbidity mortality.[@b15-jpr-9-967]

### HRQoL

HRQoL was defined by the Medical Outcomes Study 36-Item Short Form Survey Instrument version 2 (SF-36v2[@b16-jpr-9-967]; used in the survey years 2012--2014) or the 12-item Short-Form Survey Instrument version 2 (SF-12v2[@b17-jpr-9-967]; used in the survey year 2011). Eight health domains (ie, physical functioning, physical role limitations, body pain, general health, vitality, social functioning, emotional role limitations, and mental health) and two summary scores (Physical Component Summary \[PCS\] and Mental Component Summary \[MCS\]) were calculated from the SF-36v2 or SF-12v2; higher scores indicate better health.[@b16-jpr-9-967] A health state utility score is calculated from SF-36v2 or SF-12v2 by using the SF-6D algorithm. The SF-6D-derived health utility index is scored from 0 to 1, where 1 represents perfect health.[@b18-jpr-9-967] Minimally important differences (MIDs), suggested by some previous studies, are 5 points for the norm-based health domain scores, 3 points for the norm-based component summary scores, and 0.041 points for SF-6D health utilities.[@b17-jpr-9-967],[@b19-jpr-9-967]

### Sleep difficulties

All NHWS respondents were asked the following question, "Thinking of the sleeplessness or difficulty sleeping that you experience, which of the following sleep problems or symptoms do you regularly experience?" Then, the respondents selected from a dropdown list of the symptoms that were applicable to each of them. In this study, sleep difficulties were operationalized as the presence (or absence) of "difficulty falling asleep," "waking during the night and not being able to get back to sleep," "waking up several times during the night," and "poor quality of sleep"; these items most closely reflect the insomnia domains of the *Diagnostic and Statistical Manual of Mental Disorders*, Fifth Edition,[@b20-jpr-9-967] namely sleep onset symptoms, sleep maintenance symptoms, and restorative sleep. Each sleep difficulty symptom was examined individually and had a binary response option (presence or absence).

### Work productivity and activity impairment

The Work Productivity and Activity Impairment -- General Health Questionnaire Version 2 generates four subscales assessing work productivity and activity impairment.[@b21-jpr-9-967] Absenteeism represents the percentage of time missed from work, presenteeism represents the percentage of time impaired while at work, overall work impairment is a combination of absenteeism and presenteeism, and activity impairment represents the percentage of impairment in daily activities. The Work Productivity and Activity Impairment -- General Health Questionnaire subscales are scored in the form of percentages; higher values indicate greater impairment as a result of the patient's health in the past 7 days. Absenteeism, presenteeism, and overall work impairment were only calculated for respondents who were currently employed (full-time, part-time, or self-employed), whereas activity impairment was calculated for all respondents.

### Health care resource use

Health care resource use was measured by the number of health care provider visits, the number of ER visits, and the number of times hospitalized in the past 6 months for one's own health condition (all-cause).

### Costs

The methodology for costs was adopted from the study by Sadosky et al[@b13-jpr-9-967] on lower back pain using Japan NHWS 2013, and more details can be found from this study (refer page 121--122). Briefly, the Lofland method[@b22-jpr-9-967],[@b23-jpr-9-967] was used to calculate annual indirect costs, which involved multiplying overall work impairment by estimated hourly wage rates from the Japan Basic Survey on Wage Structure 2011. As physician visits and hospitalizations for the past 6 months were asked about in the NHWS, annual direct costs were estimated by multiplying the number of physician visits and hospitalizations by two. Then, these costs were multiplied by the corresponding unit cost for physician visits and hospitalizations obtained from Ministry of Health, Labour, and Welfare, Japan. ER visits are associated with trivial independent costs in Japan and, thus, were not included in the direct cost calculation.[@b24-jpr-9-967] The NHWS respondents provided the number of hospitalizations in the past 6 months; however, the Ministry of Health, Labour, and Welfare reports only a cost per day for hospitalizations. Thus, to equate these measures, cost per day was multiplied by the average number of days per hospitalization (18.5 days as reported by the Organization for Economic Cooperation and Development).[@b25-jpr-9-967] All cost figures were calculated in Japanese yen (¥).

Statistical analyses
--------------------

### Identifying a matched control group

In order to minimize the sample size imbalance between respondents with and without fibromyalgia, a propensity score-matching process was used to identify a group without fibromyalgia that closely resembled those with fibromyalgia.[@b26-jpr-9-967] To do so, respondents with and without fibromyalgia were compared on the basis of demographics and health history variables by using *c*^2^ test (for categorical variables) and independent samples *t*-test (for continuous variables). As the number of potential predictors would exceed what could be statistically supported with the present sample size, a covariate selection process was used on the basis of both theoretical and statistical grounds.[@b27-jpr-9-967] Variables that differed between groups at a *P*-value of \<0.25 were used in a logistic regression model to predict fibromyalgia presence (ie, fibromyalgia vs no fibromyalgia).

The *P*\<0.25 cutoff was set in order to ensure that relevant variables were included even if suppression was present.[@b28-jpr-9-967] Suppression is present when the strength of the relationship between two variables is increased due to the adjustment of a third variable. Therefore, if suppression is present, a variable that has a nonsignificant correlation with fibromyalgia presence in an unadjusted analysis (eg, *P*=0.10) may, in fact, be a significant predictor of the presence of fibromyalgia by multivariable regression.

By selecting a *P*\<0.25 cutoff, exclusion of meaningful variables can be avoided. Propensity score values from this model were saved and subsequently used to match each respondent with fibromyalgia to a respondent without fibromyalgia whose propensity score value was identical. In particular, a greedy matching algorithm was used, which identified controls to match to a single case at up to eight decimal places of the propensity score (and as little as one decimal place, if no other suitable control was identified).[@b29-jpr-9-967] Matched respondents were considered a matched control group without fibromyalgia, and the respondents who were not matched were excluded from further analyses.

### Postmatch considerations

Postmatch, respondents with fibromyalgia and matched controls were compared with respect to demographics and health history variables by using *χ*^2^ test and independent samples *t*-test. These analyses tested the degree of balance between groups and determined whether any variables should further be controlled. Following recommendations by Austin,[@b30-jpr-9-967] variables that had a standardized mean difference of ≥0.10 between groups postmatch were considered as covariates in subsequent multivariable analyses. In particular, if any demographic or health history variable differed between groups postmatch, then a series of generalized linear models was conducted to predict each outcome, specifying the appropriate distribution (eg, binomial for sleep difficulties, due to binary responses on sleep items, normal for health status variables, and negative binomial for all count outcomes \[Work Productivity and Activity Impairment metrics, health care resource use, and costs\]). These models had fibromyalgia status (yes vs no) as the primary independent variable, with any variable that significantly differed between fibromyalgia status groups included as covariates. Adjusted means and 95% confidence intervals (CIs) were reported from these models. Any two-sided *P*-values \<0.05 were considered to be statistically significant.

Results
=======

Sample demographics and matching results
----------------------------------------

Of those who reported fibromyalgia (n=128), the average age was 42.62 years, and 59.4% were female. The majority had less than a university degree (59.4%), national health insurance (53.1%), body mass index categories of acceptable risk (39.8%) or increased risk (25.8%), consumed alcohol (63.3%), and did not exercise (56.2%; [Table 1](#t1-jpr-9-967){ref-type="table"}). In terms of disease characteristics, the mean number of years experiencing fibromyalgia was 6.15 (standard deviation =6.68), and most respondents reported either mild (32.0%) or moderate (43.0%) levels of pain severity ([Table 2](#t2-jpr-9-967){ref-type="table"}). In addition, the most commonly used *R~x~* for fibromyalgia was pregabalin (31.3%), duloxetine hydrochloride (10.9%), and loxoprofen (10.9%; [Table 2](#t2-jpr-9-967){ref-type="table"}).

Postmatch, several demographics and health characteristics between the fibromyalgia and nonfibromyalgia groups had standardized mean differences \>0.10, thus representing an imbalance between groups ([Table 1](#t1-jpr-9-967){ref-type="table"}). Therefore, age, sex, income, insurance, body mass index, and exercise were used as covariates in multivariable analyses comparing outcomes between the fibromyalgia and nonfibromyalgia groups. Comorbidity burden (Charlson comorbidity index), survey year, education, smoking behavior, and alcohol consumption had standardized mean differences \<0.10, indicating that these characteristics were similar between groups as a result of matching.

HRQoL burden
------------

### Unadjusted comparisons

Unadjusted two-sample comparisons revealed that those with fibromyalgia, relative to those without fibromyalgia, had substantially lower HRQoL, including lower SF-6D health utilities, MCS, PCS, and all of the health domain scores (eg, bodily pain, role physical, and vitality scale; [Table 3](#t3-jpr-9-967){ref-type="table"}). In addition, incidences of sleep difficulties among those with fibromyalgia were also much higher than among those without fibromyalgia, including "difficulty falling asleep," "waking during the night and not being able to get back to sleep," "waking up several times during the night," and "poor sleep quality" ([Table 3](#t3-jpr-9-967){ref-type="table"}).

### Adjusted comparisons

After adjusting for covariates, results were consistent with unadjusted two-sample comparisons between those with fibromyalgia and those without fibromyalgia. Those with fibromyalgia scored 12.72 points lower on MCS (adjusted means =33.15 \[CI =31.45%--34.86%\] vs 45.88 \[CI =44.17%--47.59%\]), 11.59 points lower on PCS (adjusted means =39.22 \[CI =37.84%--40.60%\] vs 50.81 \[CI =49.43%--52.19%\]), and 0.185 points lower on health utilities (adjusted means =0.547 \[CI =0.528%--0.566%\] vs 0.732 \[CI =0.713%--0.751%\]), relative to those without fibromyalgia (all *P*\<0.001). In addition, all of the health domain scores were nearly 10--16 points lower for those with fibromyalgia ([Figure 2](#f2-jpr-9-967){ref-type="fig"}). Respondents with fibromyalgia also experienced significantly greater incidences of all sleep difficulties assessed ([Figure 3](#f3-jpr-9-967){ref-type="fig"}). Notably, compared to those without fibromyalgia, those with fibromyalgia experienced nearly 13 times the odds of "waking during the night and not being able to get back to sleep" (adjusted proportions =34.7% \[CI =25.6%--45.0%\] vs 3.9% \[CI =1.7%--8.8%\]) and seven times the odds of "waking up several times during the night" (adjusted proportions =30.1% \[CI =21.8%--40.0%\] vs 5.5% \[CI =2.6%--11.1%\]), all with *P*\<0.001.

Economic burden
---------------

### Unadjusted comparisons

Unadjusted two-sample comparisons showed greater economic burden among fibromyalgia respondents, compared to those without fibromyalgia. Fibromyalgia respondents had nearly seven times as much absenteeism and approximately twice as much presenteeism, overall work impairment, and activity impairment ([Table 3](#t3-jpr-9-967){ref-type="table"}). Furthermore, health care resource use was much higher among respondents with fibromyalgia, with approximately twice as many health care provider visits, eleven times as many ER visits, and five times as many hospitalizations than among respondents without fibromyalgia ([Table 3](#t3-jpr-9-967){ref-type="table"}). Consequently, indirect costs were approximately twice as high and direct costs were more than four times as high among respondents with fibromyalgia ([Table 3](#t3-jpr-9-967){ref-type="table"}).

### Adjusted comparisons

Results from adjusted comparisons were consistent with unadjusted comparisons showing substantially greater economic burden among those with fibromyalgia, compared to those without fibromyalgia. Those with fibromyalgia experienced nearly ten times as much absenteeism (adjusted means =24.54% \[CI =12.68%--47.49%\] vs 2.57% \[CI =1.37%--4.81%\]), twice as much presenteeism (adjusted means =60.08% \[CI =46.69%--77.30%\] vs 28.45% \[CI =22.82%--35.47%\]), and twice as much overall work impairment (adjusted means =69.43% \[CI =55.22%--87.30%\] vs 29.02% \[CI =23.39%--36.01%\]), all with *P*\<0.001. Activity impairment was also twice as high among those with fibromyalgia compared to those without fibromyalgia (adjusted means =64.76% \[CI =56.88%--73.75%\] vs 28.48% \[CI =24.98%--32.46%\]; *P*\<0.001; [Figure 4](#f4-jpr-9-967){ref-type="fig"}). For health care resource use, respondents with fibromyalgia had nearly three times as many health care provider visits (adjusted means =21.29 \[CI =16.66%--27.23%\] vs 7.17 \[CI =5.56%--9.25%\]), nearly 14 times as many ER visits (adjusted means =0.75 \[CI =0.46%--1.21%\] vs 0.05 \[CI =0.02%--0.13%\]) and nearly eight times as many hospitalizations (adjusted means =0.89 \[CI =0.51%--1.54%\] vs 0.11 \[CI =0.05%--0.24%\]), all with *P*\<0.001 ([Figure 5](#f5-jpr-9-967){ref-type="fig"}).

As a result of greater work productivity loss and health care resource use, indirect and direct costs were higher among respondents with fibromyalgia than among those without fibromyalgia. In particular, those with fibromyalgia incurred indirect costs that were more than twice as high (adjusted means =¥2,826,395 \[CI =¥2,223,091--¥3,593,425\] vs ¥1,201,547 \[CI =¥959,917--¥1,503,999\]) and direct costs that were nearly six times as high (adjusted means =¥1,941,118 \[CI =¥1,262,639--¥2,984,177\] vs ¥335,140 \[CI =¥217,998--¥515,227\]), all with *P*\<0.001 ([Figure 6](#f6-jpr-9-967){ref-type="fig"}).

Discussion
==========

Compared with Japanese adults without fibromyalgia, those with fibromyalgia had lower scores on all SF-36v2/SF-12v2 component summary scores and health domain scores, as well as SF-6D health utilities. Notably, differences on MCS and PCS and SF-6D health utilities far exceeded the minimally important difference thresholds, demonstrating clinically meaningful differences in HRQoL between those with fibromyalgia and without fibromyalgia. In addition, those with fibromyalgia experienced substantially greater incidences of sleep difficulties relating to symptoms of insomnia. Hence, among Japanese adults, the findings indicated that fibromyalgia was associated with significant decreases in HRQoL.

Economic burden was also substantially greater for adults with fibromyalgia than for those without fibromyalgia. Work productivity and activity impairment were experienced \>60% of the time by adults with fibromyalgia, which was more than twice the amount experienced by those without fibromyalgia. Moreover, those with fibromyalgia used health care resources to a much greater extent, with 13 times as many ER visits, seven times as many hospitalizations, and three times as many health care provider visits. In turn, adults with fibromyalgia incurred substantially higher indirect and direct costs.

The prevalence of fibromyalgia in the current study sample (0.1%) was much smaller than the prevalence (2.1%) reported by Nakamura et al in their epidemiologic Internet survey on fibromyalgia conducted in Japan.[@b5-jpr-9-967] Yet, this latter estimate was more in accord with those reported in Western countries, such as the USA (1.75%),[@b11-jpr-9-967] Germany (2.1%),[@b31-jpr-9-967] France (1.6%),[@b32-jpr-9-967] and the UK (5.4%).[@b33-jpr-9-967] One likely explanation for these differences in reported prevalence is that in the current study prevalence of fibromyalgia was determined by respondents' self-reported physician diagnosis of fibromyalgia, whereas in the other studies ACR diagnostic criteria were used to estimate the prevalence.

There are likely vast differences in diagnosis rates and actual prevalence of fibromyalgia as there is some evidence that fibromyalgia may be under-diagnosed in Japan. In particular, one study showed that only half of Japanese workers who met the ACR criteria for a diagnosis of fibromyalgia had reported their chronic widespread pain symptoms to a physician within the prior year. Among these individuals, only 12.5% were actually diagnosed by a physician.[@b34-jpr-9-967] In addition, among Japanese physicians who had previously treated fibromyalgia patients, less than half (44.2%) self-reported wanting to accept more patients with this chronic pain condition.[@b35-jpr-9-967] Furthermore, cross-national data showed that Japan had the lowest rate of pain reported (4.4%) and treated (26.3%), compared to other developed countries, including the USA (23.8% experienced pain and 40.1% treated) and Europe (including the UK, France, Germany, Italy, and Spain; 20.2% experienced pain and 47.0% treated).[@b36-jpr-9-967] Therefore, underdiagnosis and low acceptance of patients with fibromyalgia by physicians coupled with low pain reporting among patients may hinder the ability of Japanese patients to obtain a diagnosis and receive treatment for fibromyalgia.

Other study findings were largely consistent with the existing research on fibromyalgia. For example, findings were consistent with epidemiological research demonstrating the higher prevalence of fibromyalgia among Japanese women, compared to men.[@b5-jpr-9-967] This study's results were also in accord with prior research, outside of Japan, showing that the prevalence of sleep difficulties was significantly higher for adults with fibromyalgia than for matched controls; poor sleep quality has also been found to relate to lower HRQoL.[@b3-jpr-9-967] The findings likewise aligned with previous studies highlighting the health and economic burden of fibromyalgia, although not specific to the Japanese population. In particular, fibromyalgia has been associated with multiple comorbidities,[@b4-jpr-9-967] as well as decreases in most aspects of HRQoL.[@b8-jpr-9-967] Moreover, high direct costs, due to health care resource use, and indirect costs, due to unemployment and work productivity loss, have been ascribed to fibromyalgia.[@b8-jpr-9-967],[@b9-jpr-9-967],[@b11-jpr-9-967],[@b12-jpr-9-967]

The present study makes a number of important contributions to the literature on fibromyalgia. In particular, prior research had examined only a small range of outcomes, so the full extent of the burden associated with fibromyalgia in Japan was unknown. Furthermore, because of the aggregation of chronic pain conditions, other relevant studies had been unable to provide an indication of the burden specific to fibromyalgia in Japan. Overall, the present research was able to more comprehensively clarify, within a single study, the degree of fibromyalgia-related burden in Japan on a wide variety of health and economic outcomes.

Limitations
-----------

As previously discussed, there may be underdiagnosis of fibromyalgia in Japan. If this is indeed the case, the current study may actually provide an underestimate of the burden of fibromyalgia in Japan. Thus, the estimate of the minimum direct and indirect costs attributed to fibromyalgia in Japan in the current study may be underestimated. Future studies may provide more accurate cost estimates by using the ACR diagnostic criteria[@b1-jpr-9-967] for identifying fibromyalgia in Japan, rather than relying on self-reported diagnosis rates.

Among the fibromyalgia treatments currently used by the patients in the present study, branded pregabalin was most commonly used. It is important to note that the indirect (costs due to work productivity loss) and direct (costs due to health care resource use) cost estimates presented in the current study did not include pharmacy costs. Thus, we cannot ascertain whether pregabalin, or any other medication, contributed to the economic burden of fibromyalgia in Japan.

In addition, there are several other limitations in the current study. The study's results may be limited due to recall bias, given that outcomes were self-reported instead of clinically determined. To verify the self-reported responses, future research should incorporate independent data, such as data from patients' medical charts. Self-selection effects may likewise have biased results. For instance, younger, healthier, and/or wealthier respondents may have been more likely to participate in the study, as a function of greater access to the required technology and/or motivation to complete online surveys. Indeed, at least compared with one other fibromyalgia study in Japan, there were a greater proportion of less severe fibromyalgia patients in the current study. Among fibromyalgia patients in the current study, 21% reported severe pain; however, in the study by Nakamura et al, 52.5% reported severe pain (ie, a rating of 7--10 on the numeric pain rating scale).[@b5-jpr-9-967] If the current study sample truly has an underrepresentation of severe fibromyalgia patients, then the associations found between fibromyalgia and the health and economic outcomes examined may be underestimated. A prospective study can potentially use alternative means of survey administration, such as a paper-and-pencil format, to collect data from a broader sample of Japanese adults who may lack the access or capability to complete an online survey. In addition, generalizability of the burden associated with fibromyalgia based on a sample size of 128 may be limited. However, the study findings demonstrating the substantial humanistic and economic burden associated with fibromyalgia in Japan are in line with studies conducted in the USA and some with much larger sample sizes.[@b11-jpr-9-967],[@b12-jpr-9-967] Because of the cross-sectional, correlational design of this study, the results may not reflect longer term changes in the burden of fibromyalgia, and causal inferences cannot be made. A longitudinal study can help to address some of these shortcomings. Finally, the NHWS is designed to be a broad representative of the Japanese adult population, yet the degree to which the NHWS represents the adult population with fibromyalgia cannot be confirmed. Therefore, further research is required to corroborate these findings.

Conclusion
==========

Japanese adults with fibromyalgia evidenced substantially poorer health status and sleep quality than those without fibromyalgia. In addition, Japanese adults with fibromyalgia experienced significantly greater lost work productivity and health care use than those without fibromyalgia that resulted in significantly higher costs. Thus, the findings underscored the health and economic burden associated with fibromyalgia in Japan. Improving the rates of diagnosis and treatment for this chronic pain condition may be helpful in addressing this considerable burden.
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![Adjusted means of SF-36v2/SF-12v2 component summary and domain scores by diagnosed fibromyalgia versus nonfibromyalgia matched controls.\
**Notes:** Generalized linear models, specifying a normal distribution and an identity function, were conducted. All models were adjusted for age, sex (male vs female), income (\<¥3 MM, ¥3 MM to ¥5 MM, ¥5 MM to ¥8 MM, declined to answer vs ≥¥8 MM), BMI (underweight, increased risk, high risk, unknown vs acceptable risk), exercise (0 times vs 1+ times), and insurance type (social health, late stage elderly/other, none vs national health insurance). Error bars depict 95% confidence intervals. All comparisons between fibromyalgia and nonfibromyalgia matched controls differed significantly at *P*\<0.001. SF-36v2 was used in survey years 2012--2014; SF-12v2 was used in survey year 2011.\
**Abbreviations:** BMI, body mass index; MCS, mental component summary; PCS, physical component summary; SF-36v2, 36-Item Short Form Survey Instrument version 2; SF-12v2, 12-Item Short Form Survey Instrument version 2.](jpr-9-967Fig2){#f2-jpr-9-967}

![Adjusted proportions for sleep difficulties (% experienced) by those diagnosed with fibromyalgia versus nonfibromyalgia matched controls.\
**Notes:** Generalized linear models, specifying a binomial distribution and a logit function, due to their binary nature were conducted. All models were adjusted for age, sex (male vs female), income (\<¥3 MM, ¥3 MM to ¥5 MM, ¥5 MM to ¥8 MM, declined to answer vs ≥¥8 MM), BMI (underweight, increased risk, high risk, unknown vs acceptable risk), exercise (0 times vs 1+ times), and insurance type (social health, late stage elderly/other, none vs national health insurance). Error bars depict 95% confidence intervals. All comparisons between fibromyalgia and nonfibromyalgia matched controls differed significantly at *P*\<0.001.\
**Abbreviation:** BMI, body mass index.](jpr-9-967Fig3){#f3-jpr-9-967}

![Adjusted means for absenteeism, presenteeism, overall work impairment, and activity impairment (% impairment) by those diagnosed with fibromyalgia versus nonfibromyalgia matched controls.\
**Notes:** Generalized linear models, specifying a negative binomial distribution and a log link function, were conducted. All models adjusted for age, sex (male vs female), income (\<¥3 MM, ¥3 MM to ¥5 MM, ¥5 MM to ¥8 MM, declined to answer vs ≥¥8 MM), BMI (underweight, increased risk, high risk, unknown vs acceptable risk), exercise (0 times vs 1+ times), and insurance type (social health, late stage elderly/other, none vs national health insurance). Error bars depict 95% confidence intervals. Absenteeism, presenteeism, and overall work impairment were calculated for employed respondents only. All comparisons between fibromyalgia and nonfibromyalgia matched controls differed significantly at *P*\<0.001.\
**Abbreviation:** BMI, body mass index.](jpr-9-967Fig4){#f4-jpr-9-967}

![Adjusted mean number of health care provider visits, ER visits, and hospitalizations in the past 6 months by those diagnosed with fibromyalgia versus nonfibromyalgia matched controls.\
**Notes:** Generalized linear models, specifying a negative binomial distribution and a log link function, were conducted. All models adjusted for age, sex (male vs female), income (\<¥3 MM, ¥3 MM to ¥5 MM, ¥5 MM to ¥8 MM, declined to answer vs ≥¥8 MM), BMI (underweight, increased risk, high risk, unknown vs acceptable risk), exercise (0 times vs 1+ times), and insurance type (social health, late stage elderly/other, none vs national health insurance). Error bars depict 95% confidence intervals. All comparisons between fibromyalgia and nonfibromyalgia matched controls differed significantly at *P*\<0.001.\
**Abbreviations:** BMI, body mass index; ER, emergency room.](jpr-9-967Fig5){#f5-jpr-9-967}

![Adjusted mean indirect and direct costs (in ¥) by those diagnosed with fibromyalgia vs nonfibromyalgia matched controls.\
**Notes:** Generalized linear models, specifying a negative binomial distribution and a log link function, were conducted. All models adjusted for age, sex (male vs female), income (\<¥3 MM, ¥3 MM to ¥5 MM, ¥5 MM to ¥8 MM, declined to answer vs ≥¥8 MM), BMI (underweight, increased risk, high risk, unknown vs acceptable risk), exercise (0 times vs 1+ times), and insurance type (social health, late stage elderly/other, none vs national health insurance). Error bars depict 95% confidence intervals. All comparisons between fibromyalgia and nonfibromyalgia matched controls differed significantly at *P*\<0.001.\
**Abbreviation:** BMI, body mass index.](jpr-9-967Fig6){#f6-jpr-9-967}

###### 

Demographics and health characteristics between diagnosed fibromyalgia and nonfibromyalgia matched controls

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                Matched controls\   Diagnosed fibromyalgia\   *P*-value                                      Standardized effect size           
                                                (n=128)             (n=128)                                                                                                     
  --------------------------------------------- ------------------- ------------------------- ---------------------------------------------- -------------------------- ------- -------
  Age (mean, SD)                                46.45               15.51                     42.62                                          14.34                      0.041   −0.26

  Sex                                                                                                                                                                           

   Female                                       65.6                84                        59.4                                           76                         0.302   −0.13

   Male                                         34.4                44                        40.6                                           52                                 

  CCI score categories                                                                                                                                                          

   CCI: 0                                       62.5                80                        66.4                                           85                         0.75    0.08

   CCI: 1                                       14.8                19                        11.7                                           15                                 −0.09

   CCI: 2                                       3.1                 4                         4.7                                            6                                  0.08

   CCI: 3+                                      19.5                25                        17.2                                           22                                 −0.06

  Survey year                                                                                                                                                                   

   2011                                         21.1                27                        21.9                                           28                         0.907   0.02

   2012                                         18.8                24                        21.9                                           28                                 0.08

   2013                                         30.5                39                        27.3                                           35                                 −0.07

   2014                                         29.7                38                        28.9                                           37                                 −0.02

  Annual household income                                                                                                                                                       

   \<¥3 MM                                      39.1                50                        36.7                                           47                         0.902   −0.05

   ¥3 MM to \<¥5 MM                             17.2                22                        18.0                                           23                                 0.02

   ¥5 MM to \<¥8 MM                             10.2                13                        14.1                                           18                                 0.12

   ≥¥8 MM                                       28.9                37                        26.6                                           34                                 −0.05

   Decline to answer                            4.7                 6                         4.7                                            6                                  −0.03

  Education                                                                                                                                                                     

   Less than university degree                  61.7                79                        59.4                                           76                         0.701   −0.05

   University degree or greater                 38.3                49                        40.6                                           52                                 

  Insurance                                                                                                                                                                     

   National health insurance                    60.9                78                        53.1                                           68                         0.388   −0.16

   Social insurance                             31.2                40                        34.4                                           44                                 0.07

   Late-stage elderly insurance                 0.8                 1                         0.0[a](#tfn1-jpr-9-967){ref-type="table-fn"}   0                                  −0.13

   Other                                        3.1                 4                         7.0                                            9                                  0.18

   None of the above                            3.9                 5                         5.5                                            7                                  0.05

  BMI categories                                                                                                                                                                

   Underweight                                  20.3                26                        15.6                                           20                         0.776   −0.12

   Acceptable risk                              39.8                51                        39.8                                           51                                 0.00

   Increased risk                               21.9                28                        25.8                                           33                                 0.09

   High risk                                    12.5                16                        14.8                                           19                                 0.07

   Unknown                                      5.5                 7                         3.9                                            5                                  −0.12

  Smoking behavior                                                                                                                                                              

   Current smoker                               30.5                39                        32.8                                           42                         0.922   0.05

   Former smoker                                20.3                26                        19.5                                           25                                 −0.02

   Never smoker                                 49.2                63                        47.7                                           61                                 −0.03

  Alcohol use                                                                                                                                                                   

   Abstains                                     38.3                49                        36.7                                           47                         0.796   −0.03

   Consumes                                     61.7                79                        63.3                                           81                                 

  Exercise behavior                                                                                                                                                             

   Exercise: 0 day/month                        61.7                79                        56.2                                           72                         0.374   −0.11

   Exercise: 1+ times 20 min for ≥1 day/month   38.3                49                        43.8                                           56                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

This category is not used in comparisons because its column proportion is equal to 0 or 1.

**Abbreviations:** BMI, body mass index; CCI, Charlson comorbidity index; SD, standard deviation.

###### 

Disease characteristics and current treatment among those diagnosed with fibromyalgia

  ----------------------------------------------------------------
                                  Diagnosed fibromyalgia\   
                                  (n=128)                   
  ------------------------------- ------------------------- ------
  Number of years experienced     6.15                      6.68

  with fibromyalgia                                         

  Severity of fibromyalgia pain                             

   Mild                           32.0                      41

   Moderate                       43.0                      55

   Severe                         21.1                      27

   Unknown                        3.9                       5

  *R~x~* for fibromyalgia                                   

   Pregabalin                     31.3                      40

   Duloxetine hydrochloride       10.9                      14

   Loxoprofen                     10.9                      14

   Diclofenac                     9.4                       12

   Diclofenac sodium              2.3                       3

   Morphine sulfate               2.3                       3

   Celecoxib                      1.6                       2

   Indomethacin                   1.6                       2

   Codeine phosphate              0.8                       1

   Fentanyl                       0.8                       1

   Lornoxicam                     0.8                       1

   Tramadol hydrochloride         0.8                       1

   Carbamazepine                  0.8                       1

   Indomethacin                   0.8                       1

   Other                          10.2                      13
  ----------------------------------------------------------------

**Abbreviation:** SD, standard deviation.

###### 

Unadjusted health and economic outcomes between those diagnosed with fibromyalgia and nonfibromyalgia matched controls

                                                                           Matched controls (n =128)   Diagnosed fibromyalgia (n =128)   *P*-value                
  ------------------------------------------------------------------------ --------------------------- --------------------------------- ----------- ------------ ---------
  SF-36v2/SF-12v2                                                                                                                                                 
   Mental Component Summary                                                46.36                       10.52                             32.67       11.81        \<0.001
   Physical Component Summary                                              50.60                       7.92                              39.43       9.02         \<0.001
   SF-6D Health State Utility Score                                        0.740                       0.133                             0.540       0.108        \<0.001
   Bodily Pain Scale                                                       50.45                       9.17                              34.89       11.30        \<0.001
   General Health Scale                                                    44.34                       10.52                             34.02       11.14        \<0.001
   Mental Health Scale                                                     45.96                       11.13                             33.92       12.04        \<0.001
   Physical Functioning Scale                                              51.73                       8.37                              41.81       10.99        \<0.001
   Role Emotional Scale                                                    48.24                       11.03                             31.80       13.22        \<0.001
   Role Physical Scale                                                     49.79                       9.54                              35.38       10.90        \<0.001
   Social Functioning Scale                                                48.82                       10.09                             34.22       11.27        \<0.001
   Vitality Scale                                                          48.89                       10.93                             38.18       11.49        \<0.001
  Difficulty falling asleep (%, n)                                         20.3                        25                                52.6        60           \<0.001
  Waking during the night and not being able to get back to sleep (%, n)   6.5                         8                                 36.0        41           \<0.001
  Waking up several times during the night (%, n)                          6.5                         8                                 32.5        37           \<0.001
  Poor quality of sleep (%, n)                                             19.5                        24                                44.7        51           \<0.001
  \% Absenteeism[\*](#tfn5-jpr-9-967){ref-type="table-fn"}                 4.09                        11.27                             27.08       35.05        \<0.001
  \% Presenteeism[\*\*](#tfn6-jpr-9-967){ref-type="table-fn"}              33.04                       31.12                             53.64       26.62        \<0.001
  \% Overall work impairment[\*](#tfn5-jpr-9-967){ref-type="table-fn"}     33.13                       32.21                             64.22       28.89        \<0.001
  \% Activity impairment                                                   30.70                       28.65                             64.22       26.01        \<0.001
  Health care provider visits in past 6 months                             10.83                       37.21                             26.29       44.53        0.003
  ER visits in past 6 months                                               0.25                        1.23                              2.77        10.31        0.006
  Hospitalizations in past 6 months                                        0.63                        3.25                              3.30        10.85        0.008
  Direct costs (in ¥)                                                      959,787                     4,390,498                         4,512,359   13,721,280   0.006
  Indirect costs (in ¥)                                                    1,335,400                   1,381,245                         2,725,934   1,484,848    \<0.001

**Notes:** SF-36v2 was used in survey years 2012--2014; SF-12v2 was used in survey year 2011.

Calculated for employed only: nonfibromyalgia matched controls with n=67; diagnosed fibromyalgia with n=60.

Calculated for employed only: nonfibromyalgia matched controls with n=69; diagnosed fibromyalgia with n=55.

**Abbreviations:** ER, emergency room; SD, standard deviation; SF-36v2, 36-Item Short Form Survey Instrument version 2; SF-12v2, 12-Item Short Form Survey Instrument version 2.
